Hsien-Che Ou

Hsien-Che Ou

Auto-generated profile, based on publicly available information

Hsien-Che Ou

Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in The International Journal of Medical Robotics and Computer Assisted Surgery
Verified
Journal Article
Open access
CYChe Hsueh Yang
Che Hsueh Yang
HOHsien Che Ou
Hsien Che Ou
YJYung‐Shun Juan
Yung‐Shun Juan
RNRagavan Narasimhan
Ragavan Narasimhan
AMAlex Mottrie
Alex Mottrie
MTMin Che Tung
Min Che Tung
Background: Among the novel robotic platforms, the Hugo RAS system is the second most studied platform, next to the da Vinci system, and we aim to address our experiences in radical prostatectomy (RP) with the Hugo RAS system.Methods: We recorded our first 12 cases of prostate cancer undergoing RP with the Hugo RAS system. The median console time was 145 min and median hospital stay was 7 days. Hedge’ g was applied to search for the cut‐off case in four parameters in surgeries.Results: Pre‐console preparation was significantly improved after the first seven cases, and the console time was remarkably shortened after the first two cases. The intraoperative pause for trouble shooting was remarkably shortened after the first three cases.Conclusions: We found that RP with the Hugo RAS system was feasible, and the learning curve was short as surgeons may benefit from the previous experience with the da Vinci system.

Verified
Journal Article
Open access
PDF file
HCHaoHan Chang
HaoHan Chang
PTPai-Chi Teng
Pai-Chi Teng
CLChia-Hsin Liu
Chia-Hsin Liu
YLYung-Lun Lin
Yung-Lun Lin
SWShu-Chi Wang
Shu-Chi Wang
CLCHIA-YANG LI
CHIA-YANG LI
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have changed the treatment of advanced bladder cancer, but only a minority of patients benefit. We asked whether expression of PD-1 pathway genes carries prognostic information in bladder cancer. Sixty-eight genes annotated to the PD-1 signaling, CD28 co-stimulation, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitory signaling pathways in Reactome were examined in The Cancer Genome Atlas bladder urothelial carcinoma cohort (TCGA-BLCA). Genes differentially expressed between tumor and normal tissue were entered into a least absolute shrinkage and selection operator (LASSO) Cox model, yielding a seven-gene risk score (FYN, GRAP2, TRIB3, MAP3K8, AKT3, CD274, and CD80). In TCGA-BLCA (n = 404), the risk score was associated with overall survival independently of age, sex, and stage (hazard ratio [HR] per standard deviation 1.24, 95% confidence interval [CI] 1.11–1.39) and modestly improved discrimination over clinical variables (concordance index [C-index] 0.630 to 0.664). With coefficients and standardization fixed in advance, the score was not associated with cancer-specific survival in GSE13507 (n = 165; HR per standard deviation 1.21, 95% CI 0.83–1.77) or with outcome in four further independent cohorts, including an atezolizumab-treated cohort; in a second, smaller ICI-treated cohort it was associated with shorter survival. Gene selection was unstable under bootstrap resampling, and the signature’s associations with transcriptome-inferred immune indices were limited. This PD-1 pathway-derived signature should therefore be regarded as exploratory; its prognostic value outside TCGA-BLCA is not supported by the available evidence.